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First studies seeking for resistance mechanisms found out that relapse was dependent on
BCR-ABL. These initial experiments revealed two resistance mechanisms:
The aim of this bibliographic revision is to describe the
process of development of TKIs, specially emphasizing on
the idea of rational anti-cancer drug design as the main
strategy for overcoming resistance to therapy. I also pretend
to review the actual situation of CML thanks to TKIs, an
example of how biochemistry and molecular pathology can
highly improve medicine.
Data has been obtained using mainly the searching engine
Pubmed. Original articles of key publications of each
progress in the field have been used, as well as recent
reviews to understand the current situation.
 The complex array of mutations observed rendered difficult to envision a single second generation TKI active
against all the mutations.
 A significant number of mutations prevent the kinase domain from achieving the closed conformation
necessary for drug binding.
SOLUTION  to find inhibitors that bind Abl in the open configuration or with less stringent conformational
requirements.
Once reviewed the development procedure of TKIs and their impact on CML patients, the following conclusions can be drawn:
 Imatinib and the rest of the TKIs approved for CML represent the first case of rational drug design against a human 
malignancy
 They also are an example of the problem that resistance supposes to cancer and a way of solving them
 Finally, CML is a pathology that can take profit from personalized medicine, owing to the different mutational profile of the
different available drugs and the diversity profile of each one.
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particularly thrombocytopenia, and
pleural (10–25%) or pericardial
effusions (≤5%). Pulmonary
hypertension (<1-2%).
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occlusive events at low but significant
rates.
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CCyR: complete cytogenetic response, no Ph+ cells
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TP: toxic profile
MP: mutational profile
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 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that accounts for 15% of all cases of leukemia and has an annual
incidence of 1.5 cases per 100,000 individuals.
 CML is driven by the BCR-ABL chimeric gene product, a constitutively active tyrosine kinase. The fusion gene results from the
reciprocal balanced translocation t(9;22) (q34;q11.2), cytogenetically detected as the Philadelphia (Ph) chromosome [Fig.1].
 The BCR-ABL oncoprotein possesses constitutive kinase activity that leads to the stimulation of cell-growth pathways and reduced
apoptosis of CML cells. Examples of drivers implicated on the transduction pathways affected are RAS and MAP kinases.
 The natural course of CML consist on 3 phases: chronic phase, accelerated phase and a terminal blastic phase characterized by the
typical acute leukemia symptoms.
 Before the era of selective BCR-ABL tyrosine kinase inhibitors (TKIs), the median survival at diagnosis in CML was 3–7 years. TKIs have
revolutionized the treatment, natural history, and prognosis of CML. They have turned it in to the first cancer in which a medical
treatment can return patients to a normal life expectancy.
Gene amplification
Multiple copies of the BCR-ABL gene were
detected (by fluorescence in situ hybridization
(FISH) in CML cells of patients that relapsed4.
Point mutations
After sequencing the region corresponding to the ATP
binding pocket and the activation loop of the kinase
domain of BCR-ABL of some CML patients, a single
nucleotide change mutation (T315I) was seen to be
among those that form part of a critical hydrogen bond
with Imatinib4.
Further studies proved that 90% of CML patients who relapsed after
responding to Imatinib had different kinase domain mutations.
To gain insight into the mutation mechanisms, they modelled each
aminoacid substitution onto the crystal structure of the ABL kinase domain
bound to Imatinib. This allowed the classification of mutations into two
groups:
Mutations that directly contact Imatinib (1-3).
Mutations that prevent the conformation required for Imatinib-binding.
These include mutations in the P loop region ATP phosphate binding loop
(4-8) and in the vicinity of the activation loop (9-13).
Figure 5. ABL kinase domain
bound to Imatinib with 13
resistance mutations5.
 Despite their efficacy and optimal safety profile, all these TKI are ineffective to the T315I mutation.
 T315 residue is located on the gatekeeper region of the ATP-binding site. It participates in a critical hydrogen
bonding interaction required for high-affinity binding of the other TKIs. The T315I mutation alters the
topology of the ATP-binding pocket causing a steric clash between the side chain of the isoleucine and the
hydrogen from the drug.
SOLUTION  Structural-guided experiments of an inhibitor that accommodates into the T315I side chain thanks
to a carbon-carbon triple bond linkage on its structure. It’s the case of Ponatinib, a 500-fold potent than Imatinib
approved by FDA in 2012.
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BCR-ABL and Imatinib 3D 
structure elucidated [Fig. 4]
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1960
1988 Figure 4. Imatinib targets the relatively
well conserved ATP-binding pocket of the
catalytic domain of Abl, but it can still
achieve high specificity since it
recognizes a distinctive inactive
conformation of the activation loop of
Abl, which is seen to differ from the
inactive conformations of other kinases.
These characteristics give both high
specificity and affinity to Imatinib2.
DASATINIB (2006*) NILOTINIB (2007) BOSUTINIB (2012)
• Dual-specific Src/Abl kinase
• Binds BCR-ABL in both the
active and inactive
conformations [Fig. 8]
• Active against 14/15 Imatinib-
resistant BCR-ABL mutants
• More than 300-fold potent
than Imatinib
• Imatinib analogue, subtle
differences account for greater
potency [Fig. 7]
• Active against 32/33 Imatinib-
resistant BCR-ABL mutants [Fig. 6]
• Less activity on the usual off-
targets of Imatinib: c-Kit and
PDGFR receptors.
• Dual-specific Src/Abl
kinase
• Activity against most
Imatinib-resistant
mutants of BCR-ABL
• Minimal inhibitory activity
against c-Kit and PDGF
receptors
*Year of FDA approval
Figure 7. Binding modes of the Abl
inhibitors Imatinib, Nilotinib and
Dasatinib. Positions of the P-loop and
activating loop vary according to
whether the kinase is in an active
conformation. The green helix is helix
C, which often moves between the
active and inactive states of kinases6.
Figure 6. Abl binded to Nilotinib. The
locations of the amino acid
substitutions of carried by the
Imatinib-resistant BCR-ABL proteins
are indicated in red, orange or green,
and show different levels of sensibity
to Nilotinib. T315I mutation is also
resistant to Nilotinib2.
Figure 8. The triple bond is an unique
structural feature of Ponatinib that
allows to evade the mutant gatekeeper
residue I3157.
 After 15 years of clinical use of Imatinib and thanks to the other TKI available, CML has become the
first cancer in which a medical treatment can return patients to a normal life expectancy.
 In spite of superior data, since neither Dasatinib or Nilotinib have shown substantial amelioration in
either overall survival (OS) or progression free survival (PFS) rates over Imatinib, it continues to
represent the most commonly used TKI to treat CML frontline
 Moreover, owing to some important risks of second generation TKIs shown in the table, it may not
be worth it to take them if there is no resistance or intolerance to Imatinib.
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